Bitterroot Bio Raises $145M in Series A to Revolutionize Cardio-Immunology Medicines

Pioneering biotech company aims to reshape treatment options and improve patient outcomes in the field of cardio-immunology

Bitterroot Bio, a biotechnology company focused on developing novel immunotherapies in cardiovascular disease, announced a $145 million Series A financing round co-led by ARCH Venture Partners and Deerfield Management with participation from GV, Koch Disruptive Technologies, Alexandria Venture Investments, and others.

The company, founded in 2021 but announced publicly that it is focused on developing and delivering innovative therapeutics that harness the power of immune modulation to treat cardiovascular disease, which is the leading cause of death worldwide. The name was inspired by our co-founders’ connections to the Bitterroot mountains and river in Montana.

The company’s Board of Directors includes Steve Gillis, PhD (Chairman), Andrew ElBardissi, MD, Nick Leeper, MD, Irv Weissman, MD, and Pavan Cheruvu, MD, with Anthony Philippakis, MD, PhD, and David Mauney, MD, participating as observers.

“Cardiovascular disease represents an enormous global health burden, and there is a pressing need for safe and effective therapies,” said Dr. Cheruvu, President and CEO of Bitterroot Bio. “Our team is excited to leverage our deep expertise in immunology and cardiology to develop transformative therapies that have the potential to improve outcomes for patients with atherosclerosis and other serious cardiovascular disorders. With his decades of experience in cardiovascular drug development, Dr. Craig Basson, our Chief Medical Officer, is well-positioned to lead our talented R&D team and advance Bitterroot’s pipeline.”

Bitterroot Bio’s approach is based on the latest advances in immunology, including the identification of novel targets and the development of innovative protein therapies. The company’s lead program targeting the CD47/SIRPα pathway is designed to address the underlying dysfunction that contributes to atherosclerosis, a disease characterized by the buildup of plaque in arteries that can lead to heart attacks and stroke.

“We are pleased to partner with Bitterroot Bio as they work to bring groundbreaking medicines to patients with cardiovascular diseases,” said Dr. Steve Gillis, Chairman of the Board and managing director at ARCH Venture Partners. “The team’s depth of experience as scientific pioneers, drug developers, and accomplished biopharma leaders makes them an ideal partner for us.

Published on : 08th June, 2023